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Lipid raftPreviously we have shown that the activity of the multidrug transporter ABCC1 (multidrug resistance protein
1), and its localization in lipid rafts, depends on cortical actin (Hummel I, Klappe K, Ercan C, Kok JW. Mol.
Pharm. 2011 79, 229–40). Here we show that the efﬂux activity of the ATP-binding cassette (ABC) family
member ABCB1 (P-glycoprotein), did not depend on actin, neither in ABCB1 over expressing murine National
Institutes of Health (NIH) 3T3 MDR1 G185 cells nor in human SK-N-FI cells, which endogenously express
ABCB1. Disruption of the actin cytoskeleton, upon treatment of the cells with latrunculin B or cytochalasin
D, caused severe changes in cell and membrane morphology, and concomitant changes in the subcellular
distribution of ABCB1, as revealed by confocal laser scanning and electron microscopy. Nevertheless,
irrespective of actin perturbation, the cell surface pool of ABCB1 remained unaltered. In NIH 3T3 MDR1
G185 cells, ABCB1 is partly localized in detergent-free lipid rafts, which partitioned in two different density
gradient regions, both enriched in cholesterol and sphingolipids. Interestingly, disruption of the actin
cytoskeleton did not change the density gradient distribution of ABCB1. Our data demonstrate that the
functioning of ABCB1 as an efﬂux pump does not depend on actin, which is due to its distribution in both
cell surface-localized non-raft membrane areas and lipid raft domains, which do not depend on actin
stabilization.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The ATP-binding cassette (ABC) transporter protein ABCB1
(P-glycoprotein) is known for its involvement in multidrug resistance
(MDR) of tumor cells by preventing intracellular accumulation of
cytotoxic drugs. This transporter depends on its direct lipid environ-
ment for optimal functioning, having a higher afﬁnity for its substrates
when the surrounding lipids are in liquid-ordered phase rather than
in the liquid-disordered phase [1–3]. This is an important characteristic
of lipid rafts [4,5] and ABCB1 has indeed been associatedwith lipid rafts.
Lavie et al. [6] have shown for the ﬁrst time the association of ABCB1
with lipid rafts (caveolae) in intact cells using Triton X-100 to isolate
detergent-resistant membranes (DRMs). In 2780 AD human ovarian
tumor cells, which lack caveolae, ABCB1 was located in DRMs deﬁnedlycoprotein; ABCC1, multidrug
aveolin-1; CSA, cyclosporin A;
in and moesin; FCS, fetal calf
/MS, Liquid chromatography-
AF, multidrug activity factor;
ealth; PBS, phosphate buffered
; TCA, trichloroacetic acid
31 50 3632728.
l rights reserved.by their insolubility in the detergent Lubrol WX [7]. ABCB1 in the MDR
Chinese hamster ovary cell line CHRB30 was localized in intermediate
density domains isolated using Brij-96. These domains were shown to
be distinct from caveolae as well as classic lipid rafts, as indicated by
the differential gradient distribution of ABCB1 and the Src-family kinase
Yes kinase [8]. The mutual relationships between ABCB1 and lipid rafts
have been elegantly reviewed [9].
Lipid rafts are often considered to be highly dynamic entities, but
the actin cytoskeleton appears to have the potential to stabilize them
[10]. Interestingly, it has been inferred that ABCB1 is partially linked
to the actin cytoskeleton [11]. Moreover, ABCB1-actin association
through ezrin, radixin and moesin (ERM family proteins) has been
shown in a MDR variant of the human T-lymphoblastoma cell line
CEM-VBL100 [12]. Recently we have shown that ABCC1 is dependent
on cortical actin for its efﬂux function. Moreover, concomitant with
loss of function, ABCC1 shifted out of lipid raft density gradient
fractions [13].
In view of the observations on ABCB1-actin interactions, it is
important to note there are no studies which directly assess the effect
of actin modulation on both ABCB1-mediated efﬂux and its lipid raft
association. Therefore, for the ﬁrst time we investigated the impact
of actin on both the membrane domain localization of ABCB1 and
its efﬂux function, using confocal as well as electron microscopy,
detergent-free lipid raft analysis and efﬂux assays. We conclude that
actin disruption markedly changed cell morphology, including that
341P. Meszaros et al. / Biochimica et Biophysica Acta 1828 (2013) 340–351of the plasma membrane. However, in spite of changes in distribution
of ABCB1, there was no effect on ABCB1-mediated efﬂux. ABCB1 was
partly localized in lipid rafts and did not shift out of these lipid
rafts upon actin disruption in NIH 3T3 MDR1 G185 cells. Moreover,
ABCB1 expression on the cell surface was not changed. ABCB1 thus
remains in its normal membrane environment and therefore remains
active.
2. Materials and methods
2.1. Materials
All cell culture plastic was from Costar (Cambridge, MA, USA) and
liquids from Gibco (Invitrogen, Paisley, UK). Fetal calf serum (FCS)
was from Bodinco (Alkmaar, The Netherlands). Latrunculin B, cytocha-
lasin D, nocodazole, rhodamine 123, calcein-acetoxymethyl ester (AM),
colchicine, the monoclonal anti-β-actin antibody and the monoclonal
anti-ABCB1 antibody Clone F4 were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Alexa Fluor 488-conjugated phalloidin and Alexa
Fluor-conjugated secondary antibodies were obtained from Molecular
probes (Eugene, OR, USA). The monoclonal anti-ABCB1 antibody MRK16
was from Abnova (Taipei City, Taiwan). The polyclonal anti-caveolin-1
(Cav-1) antibody and the monoclonal anti-Rho GDP-dissociation inhibi-
tor protein (Rho-GDI) antibody were from Transduction Laboratories
(Lexington, KY, USA). The polyclonal anti-c-Src antibody was from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). SK-N-FI cells were from
ATCC (Wesel, Germany). OptiPrepwas fromAxis-Shield PoC AS (Dundee,
Scotland).
2.2. Cell culture and incubation conditions
The NIH 3T3 mouse ﬁbroblast cell line and its human MDR1-
transfected counterpart (NIH 3T3 MDR1 G185) were kindly provided
by Michael Gottesman, NIH, Bethesda, MD, USA [14]. These cells
were grown as adherent monolayer cultures in Dulbecco's modiﬁed
Eagle medium supplemented with 10% FCS, 100 units/ml penicillin,
100 μg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium pyru-
vate, under standard incubator conditions (humidiﬁed atmosphere,
5% CO2, 37 °C). The NIH 3T3 MDR1 G185 cells were kept under selec-
tive pressure by growing them in the presence of 60 ng/ml colchicine.
The cells were trypsinized 1 day prior to the experiments and
maintained without colchicine until use. The human SK-N-FI cell
line with endogenous ABCB1 expression was cultured in the same
medium, but supplemented with non-essential amino acids according
to the manufacturer's suggestion. These cells were never treated with
colchicine.
In order to disrupt the actin cytoskeleton in NIH 3T3 MDR1 G185
cells, cells were treated with cytochalasin D (10 μg/ml) or latrunculin
B (0.3 or 10 μM) for 45 min. In some cases, cells were preincubated
with nocodazole (10 μM) for 45 min to disrupt microtubules, followed
by treatment with both nocodazole and latrunculin B for 45 min [13].
SK-N-FI cells were treated similarly, except that the concentrations
for cytochalasin D and latrunculin B were 0.1 μg/ml and 0.2 μM, respec-
tively. Optimal concentrations of inhibitors were established based on
efﬁcacy of actin disruption and survival of the cells, since cell lines
display different sensitivities towards these inhibitors. All incubations
with cytoskeleton modulators and all control experiments without
these modulators were performed in medium with serum at 37 °C.
2.3. Isolation of detergent-free lipid rafts
NIH 3T3 MDR1 G185 cells were cultured to conﬂuence in 162 cm2
ﬂasks and treated with cytoskeleton modulators as mentioned above.
Detergent-free lipid rafts were isolated as described [15,16]. The whole
procedure was performed on ice. Brieﬂy, the cells were washed with
base buffer (20 mM Tris–HCl pH 7.8, 250 mM sucrose) supplementedwith 1 mMCaCl2 and 1 mMMgCl2. The cells were collected by scraping
in this solution and centrifuged for 2 min at 250 g. The resulting pellet
was suspended in 1 ml of base buffer supplemented with 1 mM CaCl2,
1 mMMgCl2 and protease inhibitors. After homogenization by passage
through a 25 Gauge needle 20 times, another centrifugation step for
10 min at 1000 g followed. The resulting post nuclear supernatant
(PNS) was collected and transferred to a separate tube. The pellet was
homogenized again in 1 ml base buffer supplemented with 1 mM
CaCl2, 1 mMMgCl2 and protease inhibitors, sheered through the needle
20 times and centrifuged. The second PNS was combined with the ﬁrst.
An equal amount of protein per sample was taken and adjusted to 2 ml
volume. Subsequently, 2 ml of base buffer containing 50% OptiPrep was
added to this 2 ml PNS. By using a gradientmixer, 8 ml gradient of 0% to
20% OptiPrep in base buffer was applied on top of this 4 ml in a centri-
fugation tube. After centrifugation for 90 min at 22,000 rpm and 4 °C in
a Beckman SW41 rotor (Beckman Coulter, Inc., Fullerton, CA, USA) frac-
tions of 1.34 ml were collected (from top to bottom) and stored at−
80 °C.
2.4. Immunoblot analysis
Protein from equal volumes of the gradient fractions was trichlo-
roacetic acid (TCA)-precipitated and resuspended in sample buffer
(5% SDS, 5% β-mercaptoethanol, 0.125 M Tris–HCl pH 6.8, 40%
glycerol). The samples were processed for Western blot as described
[16], using primary antibody against ABCB1 (1:2000), Src (1:2000),
Rho-GDI (1:2000) or β-actin (1:2000).
2.5. Analysis of cholesterol, sphingolipid and protein content of OptiPrep
gradient fractions
Lipids were extracted from pooled OptiPrep gradient fractions [17].
The cholesterol concentration was determined spectrophotometrically
by a cholesterol oxidase/peroxidase assay [18]. Sphingolipids were
extracted from pooled OptiPrep gradient fractions and analyzed by
liquid chromatography-electrospray ionization tandem mass spec-
trometry (LC-ESI–MS/MS), as described [16]. The amounts of individual
sphingolipid species were added to obtain the total sphingolipid pool.
Protein content of pooled OptiPrep gradient fractions was determined
as described by Smith et al. [19].
2.6. Detection of ABCB1-mediated rhodamine 123 efﬂux
Cells were cultured to conﬂuence in 25 cm2 ﬂasks and treated
with cytoskeleton modulators as mentioned above. Cells were
harvested by trypsinization, washed with Hank's balanced salt solu-
tion (HBSS) and incubated with the ABCB1 substrate rhodamine 123
(10 μM in HBSS) at 10 °C for 60 min. To rule out substrate concen-
tration dependent effects, all experiments were performed at 3 times
higher (30 μM) and 3 times lower concentrations (3.3 μM) of rhoda-
mine 123 as well. After the rhodamine 123 incubation cells were
washed with ice-cold HBSS. Subsequently, the cells were incubated
at 37 °C in the presence or absence of the ABCB1 inhibitor cyclosporin
A (CSA; 10 μM) during various time intervals. The efﬂux of the ﬂuo-
rescent substrate was stopped by mixing the cells with ice-cold
HBSS containing CSA (10 μM ﬁnal concentration) and keeping them
on ice. The remaining cell-associated ﬂuorescence was determined by
ﬂow cytometric analysis using an Elite ﬂow cytometer (Beckman
Coulter, Miami, FL).
2.7. Detection of ABCB1-mediated calcein efﬂux
Extrusion of calcein acetoxymethyl ester (AM) was measured
as described earlier [20] with the following changes. Cells were
trypsinized, washed, resuspended in HBSS (7×105cells/ml) and plated
in 96well solid white polystyrenemicroplates (100 μl/well). For ABCB1
Fig. 1. Validation of the ABCB1 model cell lines NIH 3T3 MDR1 G185 and SK-N-FI. (A–C) ABCB1 was detected using the anti-ABCB1 antibody Clone F4 (green) in the plasma
membrane (arrowheads) of NIH 3T3 MDR1 G185 (A) and SK-N-FI cells (C), but not in parental NIH 3T3 cells (B). Cav-1 was detected (red) in both MDR1 and parental NIH 3T3
cells in a similar pattern, i.e. on one side of the cell. Bar, 20 μm. (D, E) Whole cells (MDR1 and parental NIH 3T3) or isolated membranes (SK-N-FI) were processed for Western
blotting and ABCB1 was detected using anti-ABCB1 antibody Clone F4 in NIH 3T3 MDR1 G185 and SK-N-FI, but not in parental NIH 3T3 cells. Actin staining was used as a loading
control. (F, G) Cells were loaded with the ABCB1 substrate rhodamine 123 and efﬂux was allowed to proceed for various time intervals. NIH 3T3 MDR1 G185 (F) and SK-N-FI cells
(G), but not parental NIH 3T3 cells (F), efﬁciently efﬂuxed rhodamine 123. Data represent the mean± SD of 3 independent experiments. (H) Efﬂux in NIH 3T3 MDR1 G185 as well
as SK-N-FI cells was effectively inhibited by CSA and the residual loss of rhodamine 123 in case of NIH 3T3 MDR1 G185 cells is equal to that in parental NIH 3T3 cells, with or without
CSA. Data represent the mean± SD of 3 independent experiments.
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Then 100 μl/well calcein-AM mix (0.07 mg/ml bovine serum albumin
(BSA) in HBSS with 0.5 μM or 0.16 μM or 1.5 μM calcein-AM) oralternatively calcein-AM mix supplemented with 10 μM CSA was
added and ﬂuorescencewasmeasured in 30 s cycles on a LS55 lumines-
cence spectrometer (Perkin Elmer, Waltham, MA, USA).
Fig. 2. Disruption of actin and altered distribution of ABCB1 after cytochalasin D and latrunculin B treatment in NIH 3T3 MDR1 G185 cells. NIH 3T3 MDR1 G185 cells were untreated
(CON; A–C), or treated with 10 μg/ml cytochalasin D (CYT; D–F and S), with 0.3 μM latrunculin B (LAT 0.3; G–K), with 10 μM latrunculin B (LAT 10; L–N and T), or with 10 μM
nocodazole followed by 10 μM nocodazole+10 μM latrunculin B (NOC/LAT; P–R and W). Cells were co-stained for actin (Alexa Fluor 488-conjugated phalloidin) and ABCB1
(anti-ABCB1 antibody Clone F4). C, F, K, N, and R are the overlay images. Arrowheads indicate cortical actin or the expected location of cortical actin or alternatively ABCB1 in
the plasma membrane. Arrows indicate a patch of actin or ABCB1. The asterisk indicates stress ﬁbers. Bars, 20 μm, except for S, T, and W: 10 μm.
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MAF ¼ Rcsa−RconRcsa :
Rcsa is the slope of the calcein accumulation curve of cells incubated
with 10 μM CSA. Rcon is the slope of the calcein accumulation curve of
cells without CSA. The difference between Rcsa and Rcon depends on
the number and activity of the ABCB1 transporter molecules present
in the cell membranes. Accordingly, a high MAF value corresponds to
a high number and/or activity of ABCB1 molecules in the membrane
[20].
2.8. Detection of the ABCB1 cell surface pool
We used a modiﬁed version of the method described by Druley
et al. [21]. Cells were cultured in 25 cm2 ﬂasks, treated withcytoskeleton modulators as mentioned above and harvested by
trypsinization. The cells were kept at 4 °C to prevent recovery, washed
twice with ice-cold phosphate buffered saline (PBS) containing 1% BSA
(PBS-BSA) and centrifuged at 4 °C. 2.5×105 NIH 3T3 MDR1 G185 cells
or 2×105 SK-N-FI cells were suspended in 50 μl of ice-cold PBS-BSA
containing 40 μg/ml of human ABCB1-speciﬁcMRK16monoclonal anti-
body and incubated for 30 min at room temperature together with the
adequate cytoskeleton modulators. Primary antibody reactions were
stopped with 1 ml of ice-cold PBS and cells were centrifuged (4.5 min,
4 °C, and 1400 rpm) followed by washing once with cold PBS-BSA.
Pellets were resuspended in 50 μl cold PBS-BSA containing goat
anti-mouse Alexa Fluor 488-conjugated secondary antibody (600× or
500× diluted for NIH 3T3 MDR1 G185 and SK-N-FI cells, respectively).
The reaction mixtures were incubated at 4 °C for 40 min and the
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centrifugation (4.5 min, 4 °C, and 1400 rpm). Prior to FACS analysis
each pelletwas resuspended in 250 μl of PBS-BSA. Fluorescencewas de-
termined by ﬂow cytometric analysis as described above. A mouse
IgG2a isotype primary antibody was used (5 μl in 50 μl PBS-BSA) as
negative control according to the manufacturer's suggestions.
2.9. Confocal laser scanning ﬂuorescence microscopy
Cells were grown to 40–60% conﬂuence on glass cover slips in 12
well plates and treated with cytoskeleton modulators as mentioned
above. Cells were processed for confocal microscopy as described
[13]. Cells were stained with antibody against ABCB1 (antibody
Clone F4; 1:150) and the appropriate Alexa Fluor 546-conjugated
secondary antibody. In most experiments, cells were co-stained with
Alexa Fluor 488-conjugated phalloidin to visualize F-actin. Analysis of
the samples was performed using a TCS Leica SP2 AOBS Confocal Laser
Scanner Microscope (Leica, Heidelberg, Germany), equipped with a
HCX PL APO 63× 1.4 oil CS objective in combinationwith Leica Confocal
Software. The system was operated in the sequential mode in case of
double labeled samples. Imageswere processed usingAdobe Photoshop
CS3.Fig. 3. Disruption of actin and altered distribution of ABCB1 after cytochalasin D and latrun
with 0.1 μg/ml cytochalasin D (CYT; D–F), with 0.2 μM latrunculin B (LAT; G–K), or with 10
Cells were co-stained for actin (Alexa Fluor 488-conjugated phalloidin) and ABCB1 (anti-A
cortical actin or the expected location of cortical actin or alternatively ABCB1 in the plasma2.10. Electron microscopy
NIH 3T3 MDR1 G185 cells were grown to 70% conﬂuence in 12
well plates and treated with cytoskeleton modulators as mentioned
above. Cells were then ﬁxed in 2% PFA, 0.01% glutaraldehyde, pH
7.4, and 1 h on ice. Cells were washed with 0.1 M cacodylate buffer
(pH 7.4) for 15 min, then osmicated in 1% OsO4, 1.5% potassium
hexacyanoferrate in cacodylate buffer for 30 min, washed with
water, dehydrated in a graded series of ethanol and embedded in
Epon. Ultrathin sections (50–70 nm) were cut on a Leica Ultracut E,
counterstained with uranyl acetate and lead citrate, and examined
with a Philips CM 100 transmission electron microscope.
3. Results
3.1. Validation of the model cell lines
This study aims to determine the effect of actin on ABCB1 localiza-
tion and function and relies on the use of model cell lines that express
active ABCB1. NIH 3T3 MDR1 G185 cells express ABCB1 (green) on
the cell surface (Fig. 1A; arrowheads), while parental NIH 3T3 cells
do not (Fig. 1B). In contrast to ABCB1, both cell lines express Cav-1culin B treatment in SK-N-FI cells. SK-N-FI cells were untreated (CON; A–C), or treated
μM nocodazole followed by 10 μM nocodazole+0.2 μM latrunculin B (NOC/LAT; L–N).
BCB1 antibody Clone F4). C, F, K, and N are the overlay images. Arrowheads indicate
membrane. Arrows indicate a patch of actin or ABCB1. Bars, 20 μm.
Fig. 4. Disruption of actin results in changes in cell and plasma membrane morphology
in NIH 3T3 MDR1 G185 cells. Cells were treated as described in Fig. 2 and processed for
electron microscopy. Left images were used for assessment of cell morphology, right
images for assessment of membrane morphology. Closed bar, 10 μm and open bar,
2 μm.
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SK-N-FI cells express ABCB1 on the cell surface (Fig. 1C). Western
blotting conﬁrmed the presence of ABCB1 in NIH 3T3 MDR1 G185,
while it was not detected in parental NIH 3T3 cells (Fig. 1D). ABCB1
was also detected in SK-N-FI cells (Fig. 1E), but only after performing
a membrane isolation, thus increasing the concentration of ABCB1
relative to total protein in the sample. This was due to the lower
expression of ABCB1 in SK-N-FI cells compared to NIH 3T3 MDR1
G185 cells. In contrast to parental NIH 3T3 cells, NIH 3T3 MDR1
G185 cells effectively efﬂuxed the ABCB1 substrate rhodamine 123
(Fig. 1F). At t=0 min the loading values of rhodamine 123 were
173 A.U.±14 (n=4) for NIH 3T3 cells and 168 A.U.±18 (n=4) for
NIH 3T3 MDR1 G185 cells (Student's t-test: P=0.68). The efﬂux
from NIH 3T3 MDR1 G185 cells was strongly inhibited by CSA,
which is consistent with the notion that ABCB1 was the active trans-
porter (Fig. 1H, black columns). After CSA treatment, the remaining
rhodamine 123 level is very similar to that in NIH 3T3 cells, which
do not express ABCB1 (Fig. 1H, gray columns). Also SK-N-FI cells
effectively efﬂuxed the ABCB1 substrate rhodamine 123 (Fig. 1G),
and this was strongly inhibited by CSA (Fig. 1H, white columns). In
conclusion, NIH 3T3 MDR1 G185 and SK-N-FI cells express active
ABCB1 on the cell surface. Having validated the model cell lines, we
continue our study on ABCB1 localization and function.
3.2. Actin disruption results in changes in cell and membrane
morphology
The actin cytoskeleton (Fig. 2A) is composed of stress ﬁbers
(asterisk) and cortical actin (arrowhead) which is localized close to
the plasma membrane. We ﬁrst established the efﬁcacy of two mod-
ulators of the actin cytoskeleton, i.e. cytochalasin D and latrunculin
B, to disrupt stress ﬁbers and/or cortical actin. In case of NIH 3T3
MDR1 G185 cells (Fig. 2D), upon treatment with 10 μg/ml cytochala-
sin D stress ﬁbers were disrupted, but some continuous cortical actin
was still present (arrowhead), while actin accumulated in the cyto-
plasm and as patches (arrow) in distinct regions near the plasma
membrane. The use of a low concentration of latrunculin B (0.3 μM)
resulted in stress ﬁber disruption while cortical actin was still localized
cortically, although it was no longer continuous (Fig. 2G; arrowhead).
Treatment with 10 μM latrunculin B resulted in loss of both stress
ﬁbers and cortical actin, while actin accumulations were found close
to the plasma membrane (Fig. 2L; arrowhead). In 10 μM latrunculin
B-treated cells after pretreatment with nocodazole (Fig. 2P), linear or
punctuate cortical actin was observed (arrowhead), but more often
irregular shaped vesicle formations and actin accumulations outside
the cell (arrow). Taken together, results show that stress ﬁbers are
disrupted after both 10 μM latrunculin B and 10 μg/ml cytochalasin D
treatments. However, cortical actin is affected differently by the two
modulators at these concentrations, rendering them as valuable tools
for studying the role of cortical actin in function and localization of
ABCB1. Cell morphology is highly affected with both modulators,
resulting in cell rounding.
In case of SK-N-FI cells (Fig. 3A) cortical actin was readily visible
(arrowhead), while stress ﬁbers appeared less well organized com-
pared to NIH 3T3 MDR1 G185 cells (Fig. 2A). These cells were much
more sensitive to the actin modulators and did not survive the con-
centrations as used in NIH 3T3 MDR1 G185 cells (data not shown).
Therefore the concentrations were again optimized. Treatment with
0.1 μg/ml cytochalasin D resulted in actin accumulations throughout
the cell, while cortical actin was still observed (Fig. 3D; arrowhead).
Upon 0.2 μM latrunculin B treatment (Fig. 3G) larger actin accumula-
tions were found (arrow) and cortical actin was disrupted yielding an
irregular and discontinuous pattern near the plasma membrane
(arrowhead). Latrunculin B treatment caused cell rounding, as was
observed with NIH 3T3 MDR1 G185 cells. In 0.2 μM latrunculin
B-treated cells after pretreatment with nocodazole (Fig. 3L), linearor punctuate cortical actin was observed (arrowhead), but more
often irregular shaped actin accumulations near the cell surface
(arrow), reminiscent of the pattern observed in NIH 3T3 MDR1
G185 cells (Fig. 2P).
To characterize the morphological changes of the NIH 3T3 MDR1
G185 cells in more detail, accompanying the cytoskeletal perturba-
tions induced by the actin modulators, as clearly visible by light
microscopy (Fig. 2), we performed electron microscopy. Control
cells displayed a leading edge (Fig. 4A) with ﬁlopodia (Fig. 4B).
Upon treatment with 10 μg/ml cytochalasin D, the most apparent
change was the appearance of large membrane-enclosed structures
outside the cells, often in a distinct region near the plasma membrane
(Fig. 4C and D). This is reminiscent of the actin accumulation
observed by confocal microscopy (Fig. 2D). The use of a low concen-
tration of latrunculin B (0.3 μM) resulted in cell rounding (Fig. 4E),
Fig. 5. Disruption of actin does not result in changes in efﬂux function of ABCB1 in NIH 3T3 MDR1 G185 cells and SK-N-FI cells. Cells were treated as described in Figs. 2 or 3. Efﬂux
kinetics of rhodamine 123 under these conditions in NIH 3T3 MDR1 G185 (A–C) or SK-N-FI cells (D–F). The standard rhodamine 123 concentration was 10 μM (A, D) and this was
lowered 3× to 3.3 μM (B, E) or increased 3× to 30 μM (C, F). Values are presented as % of 0 min±SD (n=3).
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latrunculin B (10 μM) caused rounding of the cells and clustering of
organelles (Fig. 4G) while ﬁlopodia were absent from the plasma
membrane (Fig. 4H). Large vacuoles were observed beneath the
plasma membrane (Fig. 4H). Finally, when latrunculin B treatment
(10 μM) was preceded by treatment with nocodazole to disrupt the
microtubules, cell rounding was observed but no clustering of organ-
elles (Fig. 4K). Very large membrane-enclosed structures appeared
outside the cells (Fig. 4K). Large vacuoles beneath the plasma mem-
brane were apparent and the plasma membranes itself displayed
deformations (Fig. 4L). Taken together, cytochalasin D, latrunculin B
and the combination nocodazole/latrunculin B caused substantial
alterations in themorphology and integrity of the cell surface. Whether
perturbations of the actin cytoskeleton and ensuing changes in mem-
brane surface integrity might affect the distribution and function of
membrane localized ABCB1, was examined next.3.3. Actin disruption results in changes in ABCB1 localization
In control NIH 3T3 MDR1 G185 cells, ABCB1 was uniformly distrib-
uted over the plasma membrane (Fig. 2B; arrowhead). When cells
were treated with cytochalasin D, ABCB1 accumulated in patches in
a distinct region of the plasma membrane (Fig. 2E; arrow), similar
to the result obtained with actin staining (Fig. 2D). Detailed imaging
showed that the large extracellular membrane-enclosed structures,
reminiscent of those observed with electron microscopy (Fig. 4, C
and D), were positive for ABCB1 staining (Fig. 2S; arrow), as well as
the plasma membrane (arrowhead). In contrast to 0.3 μM latrunculin
B treatment (Fig. 2H), treatment with 10 μM latrunculin B resulted in
an ABCB1 staining pattern suggestive of partial internalization of
ABCB1 (Fig. 2M; arrow). Indeed, detailed imaging showed intracellu-
lar staining of ABCB1 (Fig. 2T; arrow), distinct from the plasma mem-
brane staining (arrowhead). When latrunculin B treated cells were
Fig. 6. Disruption of actin does not result in changes in efﬂux function of ABCB1 in NIH
3T3 MDR1 G185 cells and SK-N-FI cells. Cells were treated as described in Figs. 2 or 3.
Efﬂux of calcein-AM under these conditions in NIH 3T3 MDR1 G185 (A) or SK-N-FI cells
(B). The standard calcein-AM concentration was 10 μM (black bars) and this was
lowered 3× to 3.3 μM (gray bars) or increased 3× to 30 μM (white bars). Values are
presented as Multidrug Activity Factor (MAF)± SD (n=4). The MAF value is deﬁned
as: MAF ¼ Rcsa−RconRcsa , where Rcsa is the slope of the calcein accumulation curve of cells
incubated with 10 μM CSA and Rcon is the slope of the calcein accumulation curve of
cells without CSA (curves not shown; see also Section 2.7 and Ref. [20]). There were
no signiﬁcant differences between cytoskeleton conditions, as determined by the
one-way ANOVA test (P>0.05).
Fig. 7. Disruption of actin does not result in loss of association of ABCB1 with
cholesterol- and sphingolipid-enriched lipid raft fractions in NIH 3T3 MDR1 G185
cells. (A, B) Lipid rafts were isolated from cells using a detergent-free method. In the
pooled fractions, cholesterol (A) and sphingolipids (B) were measured, as well as pro-
tein content. The two lipid classes are expressed in nmol relative to protein content in
mg of the pooled gradient fractions. Data represent the mean+SD of 3 independent
experiments. *Values are signiﬁcantly (Pb0.05) different from those of fractions 5–6
(non-lipid raft membrane fractions) as determined by Student's t-test. The gradient
input values were 42.77±3.41 nmol cholesterol/mg protein of whole cells (n=3)
and 9.75±0.97 nmol sphingolipid/mg protein of whole cells (n=3). The sphingolipid
pool represented 4.3% of the total lipid pool (n=3; SDb10%). (C–E) Cells were treated
as described in Fig. 2, using 10 μM latrunculin B. Cells were then processed for lipid raft
analysis as described above (A, B) andWestern blotting. Blots were stained for the lipid
raft maker Src (C), the non-raft marker Rho-GDI (D) and ABCB1 using antibody Clone
F4 (E) and quantiﬁed with the Odyssey protocol. The numbers indicate the percentage
of a speciﬁc protein found in pooled gradient fractions, relative to the total of that
protein in the entire gradient. Data represent the mean+SD of 3 independent experi-
ments. There were no signiﬁcant differences between cytoskeleton conditions, as
determined by the one-way ANOVA test (P>0.05). The right-hand panels show repre-
sentative blots from 3 experiments concerning distribution of a given protein along the
gradient. (F, G) Cells were treated as described in Fig. 2, using 10 μM latrunculin B.
Lipid rafts were isolated from cells using a detergent-free method. In the pooled
fractions, cholesterol (F) and sphingolipids (G) were measured. The numbers indicate
the percentage of a speciﬁc lipid class (cholesterol or sphingolipids) found in pooled
gradient fractions, relative to the total of that lipid class in the entire gradient. Data
represent the mean+SD of 3 independent experiments. *Values are signiﬁcantly
(Pb0.05) different from control as determined by Student's t-test.
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in the plasma membrane was apparent (Fig. 2Q and W; arrowhead).
Moreover, the numerous and severe plasma membrane deformations
and extracellular membrane-enclosed structures arising at these con-
ditions, as revealed by electron microscopy (Fig. 4L), appeared to con-
tain ABCB1 (Fig. 2W; arrow).
The ABCB1 staining pattern in SK-N-FI cells closely resembled that
of actin in all conditions (Fig. 3,B,E,H, and M). Only in the case of
latrunculin B (Fig. 3G–K), the staining patterns slightly differed be-
tween ABCB1 and actin, with more intracellular staining of ABCB1.
In contrast to control cells, ABCB1 displayed large accumulations in
latrunculin B treated cells (Fig. 3H; arrow) as well as those cells
pretreated with nocodazole (Fig. 3M; arrow).
Taken together, our results from confocal and electron microscopy
showed that actin disruption resulted in changes in both cell and
plasma membrane morphologies as well as ABCB1 distribution, in-
cluding internal and external localizations of the transporter.
3.4. Actin disruption does not affect ABCB1-mediated efﬂux function
Wemeasured the kinetics of ABCB1-mediated efﬂux of rhodamine
123 in the absence or presence of actin modulators in both NIH 3T3
MDR1 G185 and SK-N-FI cells. The cells were ﬁrst incubated with
actin modulators, followed by analysis of the efﬂux of rhodamine
123. No differences were observed between all conditions, including
cytochalasin D or latrunculin B treatment (Fig. 5A and D). This leads
to the conclusion that ABCB1-mediated efﬂux function remainednormal, in spite of changes in the distribution of the ABC transporter.
Although the assay is reliable and the results are straightforward, we
decided to substantiate these results in two ways: 1. The experiments
were carried out with a 3 times lower (Fig. 5B and E), and also with a
3 times higher (Fig. 5C and F) concentration of the substrate rhoda-
mine 123, in order to exclude the possibility that an effect of actin
modulators becomes apparent at another substrate concentration. 2.
ABCB1-mediated efﬂux was measured also with a different assay,
employing a different substrate (calcein-AM). This was performed
in both cell lines and also with three different substrate concentra-
tions. In this assay calcein accumulation curves were generated
(data not shown) and from these curves the Multidrug Activity Factor
(MAF) was calculated, as described in Section 2.7 (see also Ref. [20]).
Also with the calcein efﬂux assay no differences were observed
between all conditions, including cytochalasin D and latrunculin B
Fig. 7 (continued).
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cells (Fig. 6B). In conclusion, under conditions where cell and mem-
brane morphology have changed, ABCB1-mediated efﬂux function
remained normal, in spite of changes in the subcellular distribution
of the ABC transporter.
3.5. Actin disruption does not affect ABCB1 localization in lipid rafts
We used a detergent-free method for the isolation of lipid rafts
from NIH 3T3 MDR1 G185 cells and ﬁrst characterized the gradient
fractions in terms of cholesterol and sphingolipid enrichment.
Fractions 1–2 were strongly and signiﬁcantly enriched in both choles-
terol (Fig. 7A) and sphingolipids (Fig. 7B). To a slightly lesser extent
this was also true for the fractions 3–4, which indicates that these
fractions truly represent lipid rafts, but with a slightly higher buoyant
density than those in fractions 1–2. In accordance with the lipid raftnature of the membranes in fraction 3–4, the lipid raft marker Src
was mostly enriched in these density gradient fractions (Fig. 7C). As
expected, the non-raft marker Rho-GDI was mostly found in the
non-raft fractions 7–9 (Fig. 7D). Some ABCB1 was found in the lipid
raft fractions 1–2, but the ABC transporter was more enriched in
the lipid raft fractions 3–4, together with Src (Fig. 7E, compare to
Fig. 7C). The largest pool of ABCB1 was not lipid raft associated, as it
was found in fractions 7–9, together with Rho-GDI (Fig. 7E, compare
to Fig. 7D). Upon actin disruption, under all conditions there was no
shift of ABCB1 out of the lipid raft fractions 3–4. The amount of
ABCB1 in the lipid raft fractions 1–2 showed a tendency to decrease
with latrunculin B treatment, either with or without preincubation
with nocodazole (Fig. 7E), but this was not signiﬁcant (P>0.05). In
conclusion, there was no effect of actin modulators on the extent of
lipid raft association of ABCB1 in NIH 3T3 MDR1 G185 cells, in accor-
dance with the absence of an effect on ABCB1-mediated efﬂux. Both
Fig. 7 (continued).
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fractions 1–2 upon latrunculin B treatment, while the association of
both lipid classes with fractions 3–4 increased (Fig. 7F and G).
3.6. Actin disruption does not affect the ABCB1 cell surface pool
Finally, we measured the pool of ABCB1 accessible from the outside
of the cells to establish whether or not this pool had changed after actin
modulation. This represents the pool on the cell surface which is likely
the only pool involved in efﬂux of ABCB1 substrates that was measured
using the rhodamine 123 and calcein assays. To this end we performed
ﬂow cytometry analysis using the ABCB1 antibody MRK16, which rec-
ognizes an external epitope of ABCB1, and a secondary ﬂuorescent anti-
body. The assay was ﬁrst optimized by constructing a saturation curve
for the MRK16 antibody for both the NIH 3T3 MDR1 G185 (Fig. 8A)
and SK-N-FI cell lines (Fig. 8C). Experiments with the actin modulators
were then performed using the optimalMRK16 antibody concentration
(40 μg/ml). There were no differences in the cell surface pool under all
conditions, including cytochalasinD and latrunculin B treatment in both
NIH 3T3 MDR1 G185 (Fig. 8B) and SK-N-FI cells (Fig. 8D). It was also
apparent and consistent with the Western blot data that ABCB1 was
much lower expressed in SK-N-FI cells compared to NIH 3T3 MDR1
G185 cells (Fig. 8D, compare to 8B). It should be noted that background
staining was negligible, as demonstrated when a mouse IgG2a isotype
primary antibody was used as negative control (Fig. 8B and D). In con-
clusion, in spite of drastic changes in plasma membrane morphology,
i.e. membrane deformations and external membrane-enclosed struc-
tures, as well as changes in distribution of ABCB1, the pool of ABCB1
expressed on the surface remained the same.
4. Discussion
In this study we have shown that ABCB1 localizes to the cell sur-
face in both ABCB1 over expressing NIH 3T3 MDR1 G185 cells andSK-N-FI cells, the latter expressing ABCB1 endogenously. The efﬂux
activity of the transporter can readily be measured in both cell lines,
in spite of the fact that ABCB1 expression is lower in SK-N-FI cells,
as indicated by cell surface labeling experiments and the notion that
Western blot detection requires prior membrane isolation in the
case of SK-N-FI cells. A major conclusion of this work is that actin dis-
ruption in either cell line does not affect the efﬂux activity of ABCB1.
Thus at conditions where cell and membrane morphologies have
changed, ABCB1-mediated efﬂux remained unaltered, in spite of
changes in the subcellular distribution of the ABC transporter. It is
important to establish this in two different cell lines, to support the
notion that it is not a cell type dependent effect. Moreover, the NIH
3T3 MDR1 G185 cell line is a murine cell line over expressing the
human ABCB1 transporter under selective pressure of colchicine.
Therefore we corroborated this result in the SK-N-FI cell line, to our
knowledge the only cell line available with endogenous expression
of the human ABCB1 in a human cell background and without any
selective pressure by cytostatics. This shows that an absence of effect
of actin disruption on ABCB1 function cannot be due to a hampered
interaction of human ABCB1 with murine actin or confounding effects
of colchicine.
The independence of ABCB1 efﬂux function on cortical actin can be
explained as follows. In both ABCB1 containing cell lines, the cell sur-
face pool of ABCB1 does not change upon actin disruption in spite of
drastic changes in membrane morphology and a redistribution of
ABCB1. Furthermore, in NIH 3T3 MDR1 G185 cells, ABCB1 only partly
localizes in lipid rafts, implying that a signiﬁcant part of ABCB1 is not
lipid raft associated and is therefore not affected by lipid raft remod-
eling due to loss of cortical actin. Moreover, concerning its lipid raft
association, the ABCB1 transporter was more abundantly associated
with lipid raft fractions 3–4, as compared to 1–2. It should be empha-
sized that fractions 3–4 are bona ﬁde lipid raft fractions, as they
contain most of the lipid raft marker Src and are relatively poor in
the non-lipid raft marker Rho-GDI. In addition, these fractions are
characterized by enrichment of the typical raft lipids cholesterol and
sphingolipids. Importantly, upon (cortical) actin disruption, neither
Src nor ABCB1 shift out of the lipid raft fractions 3–4, indicating that
the stable sequestration of the proteins in the lipid rafts that localize
to these fractions, does not depend on actin. Taken together, ABCB1
thus remains in the same membrane micro-environments at the
same levels after (cortical) actin disruption, compared to untreated
cells.
Our results reveal that next to the actin network, microtubules are
also dispensable in supporting ABCB1-mediated efﬂux and its localiza-
tion in lipid rafts, as reﬂected by the absence of an effect of pretreatment
of the cells with the microtubule disrupting agent nocodazole.
Moreover, under conditions of double treatment (nocodazole and
latrunculin B), the membrane deformations were quite severe and yet,
in spite of a presumably highly perturbed membrane organization,
ABCB1 activity was entirely compatible with that observed at control
conditions.
We therefore conclude that the concept of a functional ABCB1-
actin linkage, as described by Luciani et al. [12], is not generally applica-
ble. In this context it should be mentioned that their study on ABCB1-
actin association through ezrin, radixin and moesin was performed
in a fundamentally different cell type, the human T-lymphoblastoma
cell line CEM-VBL100. On the other hand, Bacso et al. [11] studied
ABCB1-actin linkage in the same cell line as used in the present study,
NIH 3T3 MDR1 G185 cells. These authors concluded that there is a
pool of ABCB1, which is directly linked to actin. However, the evidence
was indirect and the consequences of ABCB1 linkage to actin for
ABCB1-mediated efﬂux function were not investigated in this study.
Our results on the absence of effects of actin disruption on both
the extent of ABCB1 association with lipid rafts and the ABCB1-
mediated efﬂux function are in contrast to those recently obtained
for ABCC1[13], examined at very similar conditions as ABCB1 in
Fig. 8. Disruption of actin does not results in reduced surface expression of ABCB1 in NIH 3T3 MDR1 G185 and SK-N-FI cells. Cells were treated as described in Figs. 2 or 3 and
processed for ﬂow cytometric analysis using the ABCB1 antibody MRK16, which recognizes an external epitope of ABCB1, and a secondary ﬂuorescent antibody. (A, C) Saturation
curves were constructed for NIH 3T3 MDR1 G185 (A) and SK-N-FI (C) cells. (B, D) All cytoskeleton conditions were tested for cell surface labeling of ABCB1 in NIH 3T3 MDR1 G185
(B) and SK-N-FI cells (D) using 40 μg/ml of MRK16. A mouse IgG2a isotype primary antibody was used as negative control. For comparison, cell surface labeling of ABCB1 was also
performed in parental NIH 3T3 cells, using 40 μg/ml of MRK16 (B). Data represent the mean±SD of 3 independent experiments. There were no signiﬁcant differences between
cytoskeleton conditions, as determined by the one-way ANOVA test (P>0.05).
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latrunculin B treatment, concomitant with a disappearance from
lipid raft fractions. In fact, ABCC1 was more abundantly present in
and shifted from the lipid raft fractions 1–2, rather than from frac-
tions 3–4 [13]. Accordingly, we tend to conclude that by applying
the detergent-free raft isolation procedure different types of mem-
brane domains are isolated in fractions 1–2 versus 3–4. Both these
fractions are enriched in typical raft lipids and lipid raft markers,
but they differ in their sensitivity towards (cortical) actin disruption.
Indeed, ABCC1, associated with the lipid raft fractions 1–2, is sensitive
to (cortical) actin-disruption [13], whereas the pools of both ABCC1
[13] and ABCB1 (current study) that associate with raft fractions 3–4
are insensitive to actin disruption. In accordance with this notion,
the amount of ABCB1 in lipid raft fractions 1–2 showed a tendency
(although not signiﬁcant) to decrease with latrunculin B treatment,
while both cholesterol and sphingolipids partly shifted from the lipid
raft fractions 1–2 to the lipid raft fractions 3–4. Conﬁrmation of these
results in the SK-N-FI cell line would be of use; unfortunately, however,
we could not detect ABCB1 in the fractions obtained after lipid raft
isolation due to the low expression of ABCB1 in this cell line and the
dilution of the protein, inherent in this procedure. We could not over-
come this problem by further pooling of gradient fractions or immuno-
precipitation of ABCB1 from the gradient fractions.
We have shown previously that ABCC1 is partly in intracellular
compartments in latrunculin B treated cells and that this intracellular
localization of ABCC1 is due to internalization from the plasma mem-
brane and is not due to hampered transport to the plasma membrane[13]. More importantly, this partial internalization did not affect
the efﬂux capacity of ABCC1, as measured in an efﬂux assay.
Reduced activity of ABCC1 was solely due to reduced association
with the lipid raft gradient fractions 1–2. When extrapolated to the
situation of ABCB1 in the current study, we argue that partial
internalization of ABCB1 also does not affect its efﬂux capacity. The
internalized pools of ABCC1 [13] and ABCB1 (current study) are likely
to be rather small. For ABCC1 this could not be proven because no
antibodies recognizing external epitopes of ABCC1 are available to
measure its cell surface pool. Fortunately, for ABCB1 such antibodies
are available and we exploited them in the current study to measure
the cell surface pool of ABCB1. Indeed, consistent with previous
notions, we observed that the plasma membrane pool of ABCB1 is
not changed in latrunculin B treated cells, which directly indicates
that the internalized pool must be small.
Apparently, also the partial extracellular localization of ABCB1 in
cytochalasin D treated cells did not preclude normal efﬂux capacity
of ABCB1 and did not change the measured plasma membrane pool
of ABCB1. We tend to infer that ABCB1 which is present in the extra-
cellular vesicles is active and efﬂuxes substrates normally and further
that these vesicles remain associated with the cells in the efﬂux assay
and the measurement of the cell surface pool. If these extracellular
vesicles have originated by budding from the plasma membrane,
ABCB1 is expressed on the outer leaﬂet and is thus accessible to the
antibody used for measuring the cell surface pool.
Taken together, although actin may be a promising target for strate-
gies aimed at overcoming MDR through inhibition of ABC transporter
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type of ABC transporter as well as the cell type. As revealed in the pres-
ent work, the underlying mechanism for potential failure of such strat-
egies relies ondifferences in theway the ABC transporter is organized in
the membrane with respect to its partitioning in distinct lipid rafts and
ensuing difference in terms of an association with the actin network.
Our results imply that actin cannot be considered as a universal target
in combating ABCB1-mediated drug resistance, i.e., ABCB1 efﬂux activ-
ity remains unaltered at conditions that effectively perturb the integrity
of the actin cytoskeletal network.
5. Conclusion
The ability of actin to modulate the function of ATP-binding cas-
sette (ABC) transporters, such as ABCC (multidrug resistance protein)
subfamily members is emerging. We show here that the transporter
ABCB1 (P-glycoprotein), which is highly relevant for MDR, is not af-
fected in its function by actin disruption. This is related to its persis-
tent plasma membrane as well as lipid raft localization. Therefore,
the diverse organization of ABC transporters limits opportunities to
combat drug resistance of tumor cells.
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